title: Epigenetic markers for bladder cancer in urine.
abstract: Many tumor markers for bladder cancer have been evaluated for use in detecting and monitoring bladder cancers tissue specimens, bladder washes, and urine specimens. However, none of the biomarkers reported to date has shown sufficient sensitivity and specificity to detect the entire spectrum of bladder cancers in routine clinical practice. The limited value of the established prognostic markers demands analysis of new molecular parameters having the potential to predict the prognosis of bladder cancer patients, particularly, the high-risk patients at risk of cancer progression and recurrence. Abnormal methylation of CpG islands can efficiently repress transcription of the associated gene in a manner akin to mutations and deletions. Several tumor suppressor genes correlated with bladder cancer contain CpG islands in their promoters. Markers for aberrant methylation may be a potential gateway for monitoring bladder cancer. Hypermethylation of several gene promoters was detected in urine sediment DNA from bladder cancer patients. Detection of DNA methylation in voided urine is feasible and noninvasive. Methylation is an important molecular mechanism in the development of bladder cancer and could be used as a prognostic and diagnostic marker. Aberrant patterns of epigenetic modification could, in the near future, be crucial indicators in cancer diagnosis, prognosis, and may additionally be good targets for developing novel therapies while maintaining quality of life.
authors: Department of Urology, Chungbuk National University, College of Medicine and Institute for Tumor Research, 62 Kaeshin-dong, Heungduk-gu, Cheongju 361-763 South Korea.
authors: Wun-Jae
authors: WJ
authors: Kim
authors: Yong-June
authors: YJ
authors: Kim
keywords: Bladder cancer; DNA methylation; Urine
references: Cancer Res. 2001 Dec 15;61(24):8659-63
references: 11751381
references: BJU Int. 2003 Dec;92(9):911-4
references: 14632845
references: J Natl Cancer Inst. 2006 Jul 19;98(14):996-1004
references: 16849682
references: Cancer Res. 2004 Feb 15;64(4):1425-30
references: 14973053
references: Nat Rev Cancer. 2003 Apr;3(4):253-66
references: 12671664
references: J Urol. 1999 Feb;161(2):388-94
references: 9915409
references: Yonsei Med J. 2001 Feb;42(1):14-8
references: 11293494
references: Cancer Res. 2002 Jul 15;62(14):4048-53
references: 12124340
references: J Natl Cancer Inst. 2002 May 15;94(10):755-61
references: 12011226
references: Urology. 2005 Dec;66(6 Suppl 1):35-63
references: 16399415
references: Cancer Res. 2000 Nov 1;60(21):5941-5
references: 11085508
references: Eur Urol. 2005 Jun;47(6):736-48
references: 15925067
references: Cancer Res. 2001 Apr 15;61(8):3225-9
references: 11309270
references: J Nutr. 2002 Aug;132(8 Suppl):2388S-2392S
references: 12163698
references: Cancer Res. 1998 Dec 1;58(23):5489-94
references: 9850084
references: Oncogene. 2006 Mar 23;25(13):1984-8
references: 16288222
references: J Urol. 2001 Aug;166(2):470-5
references: 11458049
references: Ann N Y Acad Sci. 2000 Jun;910:140-53; discussion 153-5
references: 10911911
references: Urology. 2003 Jan;61(1):109-18; discussion 118
references: 12559279
references: Cancer Res. 2000 Aug 1;60(15):4021-5
references: 10945601
references: Hum Mol Genet. 2001 Apr;10(7):687-92
references: 11257100
references: Nat Genet. 1994 Aug;7(4):536-40
references: 7951326
references: Anticancer Res. 1999 Jul-Aug;19(4A):2615-9
references: 10470204
references: Cancer Res. 2001 Sep 15;61(18):6688-92
references: 11559536
references: Eur Urol. 1999 Sep;36(3):225-9
references: 10450007
references: Nat Genet. 1999 Feb;21(2):163-7
references: 9988266
references: Nat Genet. 2000 Feb;24(2):132-8
references: 10655057
references: Trends Genet. 2000 Apr;16(4):168-74
references: 10729832
references: Int J Cancer. 2003 May 1;104(5):611-6
references: 12594816
references: Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):531-6
references: 9641498
references: Acta Cytol. 2006 Sep-Oct;50(5):499-506
references: 17017434
references: Am J Clin Pathol. 2001 Jul;116(1):79-86
references: 11447756
references: J Urol. 1999 May;161(5):1486-9
references: 10210378
references: Eur J Cancer. 2005 Nov;41(17):2769-78
references: 16242928
references: Urol Int. 2000;65(4):181-4
references: 11112865
references: J Urol. 1999 Oct;162(4):1388-9
references: 10492213
references: Clin Chim Acta. 2001 Mar;305(1-2):47-53
references: 11249922
references: Cancer Res. 2005 Oct 15;65(20):9347-54
references: 16230397
references: Anticancer Res. 2003 Mar-Apr;23(2A):963-7
references: 12820331
references: Cancer Res. 2000 Feb 15;60(4):892-5
references: 10706101
references: Eur Urol. 2002 Dec;42(6):622-8; discussion 628-30
references: 12477660
references: Clin Cancer Res. 2002 Feb;8(2):464-70
references: 11839665
references: Am J Pathol. 1999 Jul;155(1):105-13
references: 10393843
references: Carcinogenesis. 2006 Jan;27(1):112-6
references: 15987713
references: Clin Cancer Res. 2004 Mar 15;10(6):1887-93
references: 15041703
references: Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6
references: 9751761
references: Anal Quant Cytol. 1984 Jun;6(2):112-20
references: 6465696
references: Eur Urol. 2004 Nov;46(5):660-9; discussion 669
references: 15474280
references: J Clin Oncol. 2005 May 1;23(13):2903-10
references: 15753461
references: Clin Cancer Res. 2004 Nov 15;10(22):7457-65
references: 15569975